Feb 2, 2022 4:05 pm EST NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022
Jan 24, 2022 7:00 am EST NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
Jan 11, 2022 7:00 am EST NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
Dec 13, 2021 2:00 am EST NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary
Dec 10, 2021 7:00 am EST NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers
Nov 30, 2021 7:00 am EST NeoGenomics To Participate In The Stephens Annual Investment Conference 2021
Oct 19, 2021 2:00 am EDT NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
